Skip to content

Inhalatorial Sedation in Patient With Subarachnoid Hemorrhage (SAH) Versus Conventional Intravenous Sedation

Inhalatorial Sedation in Patient With SAH Versus Conventional Intravenous Sedation (GAS-SAH)

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00830843
Acronym
GAS-SAH
Enrollment
13
Registered
2009-01-28
Start date
2009-01-31
Completion date
2011-07-31
Last updated
2016-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, Subarachnoid Hemorrhage

Keywords

SAH, sedation, anesthesia

Brief summary

Recent study has shown that inhalatory sedation is a practicable, effective and not risky method in Intensive Care Unit. Sevoflurane effect on cerebral system have been described in previous studies: it causes an increasing of cerebral blood flow and a decrease of oxygen cerebral consumption. Clinical strategy for Subarachnoid Hemorrhage is orientated to increase cerebral blood flow to limit vasospasm phenomena after SAH. Scope of this study is to evaluate the Cerebral Blood Flow variation associated to Isoflurane sedation versus conventional sedation with propofol .

Interventions

DRUGPropofol

Propofol(3-4 mg/kg/ora)administrated for 2 hours.

DRUGIsoflurane

Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration

Sponsors

Azienda Ospedaliera San Gerardo di Monza
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* diagnosis of aSAH * indication to DVE positioning * clinical indication to sedation and assisted ventilation * indication to ICP and CBF monitoring * age \> 18

Exclusion criteria

* documented cranial hypertension (ICP\>18) not controller by liquor drainage * age \< 18.

Design outcomes

Primary

MeasureTime frame
Cerebral Blood Flowafter 2 hours of drug administration

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026